ARTICLE | Clinical News
Defactinib: Phase II suspended enrollment
October 5, 2015 7:00 AM UTC
Verastem stopped enrollment in the double-blind, international, pivotal Phase II COMMAND trial in patients with MPM after a pre-planned interim analysis showed that twice-daily 400 mg oral defactinib ...